Skip to main content
Erschienen in: World Journal of Surgery 4/2019

07.12.2018 | Original Scientific Report

Prognostic Factors of Pathological N1 Non-small Cell Lung Cancer After Curative Resection Without Adjuvant Chemotherapy

verfasst von: Youngkyu Moon, Sook Whan Sung, Jae Kil Park, Kyo Young Lee, Seha Ahn

Erschienen in: World Journal of Surgery | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this study was to evaluate the outcomes of patients with pathological N1 non-small cell lung cancer who did not receive adjuvant chemotherapy. We attempted to identify those patients for whom adjuvant chemotherapy would be indispensable.

Methods

Among 132 patients who were diagnosed with pathological N1 lung cancer at a single institution from January 2010 to December 2016 were 32 patients who did not receive adjuvant treatment after curative surgical resection. The surgical and oncological outcomes of these patients were analyzed. Candidate factors for predicting recurrence were analyzed to identify patients at high risk of recurrence.

Results

The median follow-up time for all 32 patients was 1044 days. The 5-year recurrence-free survival (RFS) and disease-specific survival rates of the patients without adjuvant therapy were 50.3% and 77.6%, respectively. By multivariate analysis, tumors with a lepidic growth pattern [hazard ratio (HR) 0.119, p = 0.024] and extralobar lymph node metastasis (HR 6.848, p = 0.015) were significant factors predicting recurrence. The difference between the 5-year RFS rates of patients with tumors with or without a lepidic growth pattern was statistically significant (63.5% vs 40.0%, respectively; p = 0.050). The 5-year RFS rates of patients with intralobar lymph node metastasis versus those with extralobar lymph node metastasis were 63.3% and 18.8%, respectively (p = 0.002).

Conclusions

Patients with tumors without a lepidic growth pattern or with extralobar lymph node metastasis who do not receive adjuvant chemotherapy have a high recurrence rate after surgery. Therefore, these patients should be encouraged to undergo adjuvant chemotherapy if their overall condition is not a contraindication for chemotherapy.
Literatur
1.
Zurück zum Zitat Yang L, Wang S, Zhou Y et al (2017) Evaluation of the 7(th) and 8(th) editions of the AJCC/UICC TNM staging systems for lung cancer in a large North American cohort. Oncotarget 8:66784–66795PubMedPubMedCentral Yang L, Wang S, Zhou Y et al (2017) Evaluation of the 7(th) and 8(th) editions of the AJCC/UICC TNM staging systems for lung cancer in a large North American cohort. Oncotarget 8:66784–66795PubMedPubMedCentral
2.
Zurück zum Zitat Douillard JY, Tribodet H, Aubert D et al (2010) Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol 5:220–228CrossRefPubMed Douillard JY, Tribodet H, Aubert D et al (2010) Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol 5:220–228CrossRefPubMed
3.
Zurück zum Zitat Berry MF, Coleman BK, Curtis LH et al (2015) Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients. Ann Surg Oncol 22:642–648CrossRefPubMed Berry MF, Coleman BK, Curtis LH et al (2015) Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients. Ann Surg Oncol 22:642–648CrossRefPubMed
4.
Zurück zum Zitat Isaka M, Kojima H, Takahashi S et al (2018) Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: implications for adjuvant therapy. Lung Cancer 115:28–33CrossRefPubMed Isaka M, Kojima H, Takahashi S et al (2018) Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: implications for adjuvant therapy. Lung Cancer 115:28–33CrossRefPubMed
5.
Zurück zum Zitat Park BJ, Cho JH, Lee JH et al (2018) Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: the effect of postoperative adjuvant chemotherapy. Lung Cancer 117:7–13CrossRefPubMed Park BJ, Cho JH, Lee JH et al (2018) Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: the effect of postoperative adjuvant chemotherapy. Lung Cancer 117:7–13CrossRefPubMed
6.
Zurück zum Zitat Hattori A, Matsunaga T, Takamochi K et al (2017) Importance of ground glass opacity component in clinical stage IA radiologic invasive lung cancer. Ann Thorac Surg 104:313–320CrossRefPubMed Hattori A, Matsunaga T, Takamochi K et al (2017) Importance of ground glass opacity component in clinical stage IA radiologic invasive lung cancer. Ann Thorac Surg 104:313–320CrossRefPubMed
7.
Zurück zum Zitat Moon Y, Sung SW, Lee KY et al (2016) The importance of the lepidic component as a prognostic factor in stage I pulmonary adenocarcinoma. World J Surg Oncol 14:37CrossRefPubMedPubMedCentral Moon Y, Sung SW, Lee KY et al (2016) The importance of the lepidic component as a prognostic factor in stage I pulmonary adenocarcinoma. World J Surg Oncol 14:37CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Eguchi T, Kadota K, Park BJ et al (2014) The new IASLC–ATS–ERS lung adenocarcinoma classification: what the surgeon should know. Semin Thorac Cardiovasc Surg 26:210–222CrossRefPubMedPubMedCentral Eguchi T, Kadota K, Park BJ et al (2014) The new IASLC–ATS–ERS lung adenocarcinoma classification: what the surgeon should know. Semin Thorac Cardiovasc Surg 26:210–222CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Maeshima AM, Tsuta K, Asamura H et al (2012) Prognostic implication of metastasis limited to segmental (level 13) and/or subsegmental (level 14) lymph nodes in patients with surgically resected nonsmall cell lung carcinoma and pathologic N1 lymph node status. Cancer 118:4512–4518CrossRefPubMed Maeshima AM, Tsuta K, Asamura H et al (2012) Prognostic implication of metastasis limited to segmental (level 13) and/or subsegmental (level 14) lymph nodes in patients with surgically resected nonsmall cell lung carcinoma and pathologic N1 lymph node status. Cancer 118:4512–4518CrossRefPubMed
10.
Zurück zum Zitat Asamura H, Chansky K, Crowley J et al (2015) The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol 10:1675–1684CrossRefPubMed Asamura H, Chansky K, Crowley J et al (2015) The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol 10:1675–1684CrossRefPubMed
11.
Zurück zum Zitat Haney JC, Hanna JM, Berry MF et al (2014) Differential prognostic significance of extralobar and intralobar nodal metastases in patients with surgically resected stage II non-small cell lung cancer. J Thorac Cardiovasc Surg 147:1164–1168CrossRefPubMedPubMedCentral Haney JC, Hanna JM, Berry MF et al (2014) Differential prognostic significance of extralobar and intralobar nodal metastases in patients with surgically resected stage II non-small cell lung cancer. J Thorac Cardiovasc Surg 147:1164–1168CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Douillard JY, Rosell R, De Lena M et al (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7:719–727CrossRefPubMed Douillard JY, Rosell R, De Lena M et al (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7:719–727CrossRefPubMed
13.
Zurück zum Zitat Salazar MC, Rosen JE, Wang Z et al (2017) Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. JAMA Oncol 3:610–619CrossRefPubMedPubMedCentral Salazar MC, Rosen JE, Wang Z et al (2017) Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. JAMA Oncol 3:610–619CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Lu P, Sun Y, Sun Y et al (2014) The role of (18)F-FDG PET/CT for evaluation of metastatic mediastinal lymph nodes in patients with lung squamous-cell carcinoma or adenocarcinoma. Lung Cancer 85:53–58CrossRefPubMed Lu P, Sun Y, Sun Y et al (2014) The role of (18)F-FDG PET/CT for evaluation of metastatic mediastinal lymph nodes in patients with lung squamous-cell carcinoma or adenocarcinoma. Lung Cancer 85:53–58CrossRefPubMed
15.
Zurück zum Zitat Moon Y, Kim KS, Lee KY et al (2016) Clinicopathologic factors associated with occult lymph node metastasis in patients with clinically diagnosed N0 lung adenocarcinoma. Ann Thorac Surg 101:1928–1935CrossRefPubMed Moon Y, Kim KS, Lee KY et al (2016) Clinicopathologic factors associated with occult lymph node metastasis in patients with clinically diagnosed N0 lung adenocarcinoma. Ann Thorac Surg 101:1928–1935CrossRefPubMed
16.
Zurück zum Zitat Travis WD, Brambilla E, Nicholson AG et al (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243–1260CrossRefPubMed Travis WD, Brambilla E, Nicholson AG et al (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243–1260CrossRefPubMed
17.
Zurück zum Zitat Rusch VW, Asamura H, Watanabe H et al (2009) The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 4:568–577CrossRefPubMed Rusch VW, Asamura H, Watanabe H et al (2009) The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 4:568–577CrossRefPubMed
18.
Zurück zum Zitat Jonnalagadda S, Smith C, Mhango G et al (2011) The number of lymph node metastases as a prognostic factor in patients with N1 non-small cell lung cancer. Chest 140:433–440CrossRefPubMedPubMedCentral Jonnalagadda S, Smith C, Mhango G et al (2011) The number of lymph node metastases as a prognostic factor in patients with N1 non-small cell lung cancer. Chest 140:433–440CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Jonnalagadda S, Arcinega J, Smith C et al (2011) Validation of the lymph node ratio as a prognostic factor in patients with N1 nonsmall cell lung cancer. Cancer 117:4724–4731CrossRefPubMedPubMedCentral Jonnalagadda S, Arcinega J, Smith C et al (2011) Validation of the lymph node ratio as a prognostic factor in patients with N1 nonsmall cell lung cancer. Cancer 117:4724–4731CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Moon Y, Kim KS, Sung SW et al (2014) Correlation of histological components with tumor invasion in pulmonary adenocarcinoma. World J Surg Oncol 12:388CrossRefPubMedPubMedCentral Moon Y, Kim KS, Sung SW et al (2014) Correlation of histological components with tumor invasion in pulmonary adenocarcinoma. World J Surg Oncol 12:388CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Moon Y, Lee KY, Sung SW et al (2016) Differing histopathology and prognosis in pulmonary adenocarcinoma at central and peripheral locations. J Thorac Dis 8:169–177PubMedPubMedCentral Moon Y, Lee KY, Sung SW et al (2016) Differing histopathology and prognosis in pulmonary adenocarcinoma at central and peripheral locations. J Thorac Dis 8:169–177PubMedPubMedCentral
22.
Zurück zum Zitat Kadota K, Villena-Vargas J, Yoshizawa A et al (2014) Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol 38:448–460CrossRefPubMedPubMedCentral Kadota K, Villena-Vargas J, Yoshizawa A et al (2014) Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol 38:448–460CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Tremblay L, Deslauriers J (2013) What is the most practical, optimal, and cost effective method for performing follow-up after lung cancer surgery, and by whom should it be done? Thorac Surg Clin 23:429–436CrossRefPubMed Tremblay L, Deslauriers J (2013) What is the most practical, optimal, and cost effective method for performing follow-up after lung cancer surgery, and by whom should it be done? Thorac Surg Clin 23:429–436CrossRefPubMed
24.
Zurück zum Zitat Kiankhooy A, Taylor MD, LaPar DJ et al (2014) Predictors of early recurrence for node-negative t1 to t2b non-small cell lung cancer. Ann Thorac Surg 98:1175–1183CrossRefPubMed Kiankhooy A, Taylor MD, LaPar DJ et al (2014) Predictors of early recurrence for node-negative t1 to t2b non-small cell lung cancer. Ann Thorac Surg 98:1175–1183CrossRefPubMed
Metadaten
Titel
Prognostic Factors of Pathological N1 Non-small Cell Lung Cancer After Curative Resection Without Adjuvant Chemotherapy
verfasst von
Youngkyu Moon
Sook Whan Sung
Jae Kil Park
Kyo Young Lee
Seha Ahn
Publikationsdatum
07.12.2018
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 4/2019
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-018-04875-y

Weitere Artikel der Ausgabe 4/2019

World Journal of Surgery 4/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.